AIC adds new drugs
By HME News Staff
Updated 9:01 AM CDT, Mon March 25, 2024
DALLAS – AIC, a division of AIS Healthcare, now offers GLASSIA and ARALAST NP, manufactured by Takeda, for the treatment of adult patients with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI (alpha1-antitrypsin deficiency). The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized infusion services to patients in their home or at an infusion suite setting. “We’re excited and proud to be able to add Takeda’s Alpha1 therapies to our growing portfolio of infusion therapies,” said Jud Hall, president at AIC. “The addition of GLASSIA and ARALAST NP can help us provide patients with more options to meet individual treatment needs.” Approved by the U.S. Food and Drug Administration (FDA) in 2010 and 2002, respectively, GLASSIA and ARALAST NP are Alpha1-Proteinase Inhibitors (Human) (Alpha1-PI) indicated for chronic augmentation therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI. Both GLASSIA and ARALAST NP are now available at all AIC locations (Valdosta, Ga., Birmingham, Ala., Panama City, Fla., and Dallas). AIC is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).
Comments